Bruker Corporation’s Microbiology & Infection Diagnostics division is showcasing its expanding portfolio at ASM Microbe 2026 in Washington. The portfolio spans microbial identification, sepsis diagnostics, molecular testing, and next-generation sequencing workflows, with a focus on clinical research and faster infectious disease diagnostics.
Bruker is highlighting expanded clinical capabilities for the MALDI Biotyper® CA System through FDA Claims 7 and 8. The updates support broader microbial identification in clinical laboratories.
The enhancements include MBT Compass® HT CA software, MBT FAST™ Shuttle US IVD, and an expanded FDA-cleared reference library covering 549 clinically validated microbial species across bacteria, anaerobes, and yeasts.
Bruker is also focusing on bloodstream infection and sepsis diagnostics. The company has outlined a new vision to advance rapid antimicrobial susceptibility testing in clinical microbiology.
Together with the MALDI Biotyper CA System and Bruker Arc™ automated sample preparation solution for positive blood cultures, the rapid AST workflow under development aims to enable faster, actionable diagnostics for earlier clinical decision-making in critically ill patients.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
“We believe the future of microbiology lies in integrated innovations that can deliver faster, clinically actionable answers for some of the most critical patient conditions, including sepsis,” remarks Carla Schneider, Bruker’s Director Commercial Operations, Microbiology & Infection Diagnostics - Americas.
Bruker is introducing several new solutions for MALDI Biotyper RUO/GP systems to the U.S. market, following their recent launch at ESCMID Global 2026. These include the MBT Easy T® Kit (GP), MBT Compass HT RUO/GP v.500 with an expanded library covering 5,325 species, and the MBT HT Library Creator (RUO).
The latest RUO/GP library expansion adds more than 600 species, including approximately 30 percent improved coverage of filamentous fungi. The MBT HT Library Creator (RUO) Module enables laboratories to generate, manage, and share custom libraries within the MBT Compass HT environment for research purposes.
The company is also introducing new classifiers for the IR Biotyper® to enhance rapid outbreak investigation and surveillance capabilities.
In the realm of NGS and molecular diagnostics, Bruker is introducing MBioSEQ® Ridom Typer software (RUO) to the U.S. market at ASM Microbe 2026. The software supports reflex NGS testing as an extension of microbial identification and outbreak analysis workflows.
Together, MALDI Biotyper, IR Biotyper, and MBioSEQ Ridom Typer reflex testing create a workflow that helps laboratories move from identification to epidemiological insight and genomic characterization.
“At ASM Microbe 2026, we are showcasing how our expanding portfolio and innovation pipeline are helping laboratories move toward faster decision-making - including the next wave of solutions for rapid positive blood culture analysis,” Schneider notes. “This is reflected in our U.S. microbiology business, where robust demand for MALDI Biotyper and IR Biotyper solutions drove 140 new system placements in 2025, complemented by double-digit consumables growth. We’ve seen this double-digit US growth momentum continue into 2026, with both systems and consumables performing strongly.”
This article is based on a press release issued by Bruker.
